#United States #New York #Securities Fraud #Pomerantz LLP #Agios Pharmaceuticals

Pomerantz Law Firm Investigates Claims for Agios Pharmaceuticals' Investors

On October 18, 2025, the Pomerantz Law Firm, a prominent name in securities class actions, launched an investigation on behalf of investors in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). This inquiry is particularly significant given the recent events surrounding the company's stock and its implications for investor confidence.

Context of Investigation

The crux of the investigation revolves around claims that Agios and its management may have engaged in securities fraud or other unlawful business practices. Such actions, if proven, could have dire consequences for the company and its shareholders.

The catalyst for this investigation came on September 4, 2025, when Agios announced a delay from the U.S. Food and Drug Administration (FDA) regarding the review of their new drug application for PYRUKYND®(mitapivat). This oral pyruvate kinase activator treatment targets adult patients suffering from non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- and beta-thalassemia.

Stock Market Reaction

With the announcement of the delayed FDA review, Agios's share price took a notable hit, plunging by $4.48 or 11.03%, settling at $36.13 per share at the close of trading on the same day. This fall raised eyebrows among investors and prompted the Pomerantz Law Firm to gather information from those affected by this downturn.

About Pomerantz LLP

Founded over 80 years ago by Abraham L. Pomerantz, a respected figure in the realm of class action litigation, the Pomerantz Law Firm has established itself as a leading force in defending the rights of investors. With offices situated in major cities such as New York, Chicago, Los Angeles, London, and Paris, the firm is dedicated to tackling issues ranging from securities fraud to breaches of fiduciary duties and corporate misconduct.

Pomerantz's expertise is considerable, with a history of recovering substantial damages for class members in various litigation cases. The firm encourages investors who may have suffered losses related to Agios Pharmaceuticals to reach out for a consultation.

What Investors Should Do Next

Investors with interests in Agios Pharmaceuticals are urged to contact Danielle Peyton at Pomerantz for personalized advice and information regarding joining the class action. Contact details are as follows:

• - Email: [email protected]
• - Phone: 646-581-9980, ext. 7980.

This situation serves as a reminder of the volatility that can surround pharmaceutical companies and the intricacies involved in drug approval processes. Potential impacts on a company’s financial health can be swift and severe, underscoring the importance of being informed about the governance and operational practices of firms you invest in.

In conclusion, it is critical for investors to stay informed and proactive during such investigations. As developments unfold, the Pomerantz Law Firm will keep stakeholders updated to ensure that the rights of investors are vigorously defended. Investors are encouraged to monitor the situation closely as it progresses and to utilize the resources available for their protection.

For more information and updates on this investigation, interested parties can visit Pomerantz Law Firm's website.

• ---